M&A / Deals Parabilis follows hefty Regeneron deal with IPO push BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Post navigation Previous: AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritisNext: Beam one-ups Wave as both show promise of genetic editing for AATD Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026